miRNA control of apoptotic programs: Focus on ovarian cancer

Expert Review of Molecular Diagnostics

Volumn 11, Issue 3, 2011, Pages 277-286

  Mezzanzanica, Delia ^a   Canevari, Silvana ^a   Cecco, Loris De ^a   Bagnoli, Marina ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

apoptosis; apoptosis regulation; drug resistance; microRNA; miRNA; ovarian cancer

Indexed keywords

APOPTOSIS INHIBITOR; APOPTOSIS REGULATORY PROTEIN; B RAF KINASE; BETA CATENIN; BMI1 PROTEIN; CASPASE 10; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CISPLATIN; DNA; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS ASSOCIATED PHOSPHATASE 1; FLICE INHIBITORY PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; I KAPPA B KINASE BETA; K RAS PROTEIN; MICRORNA; PACLITAXEL; PED PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 3; PUMA PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CARCINOMA CELL; CELL SURVIVAL; DNA DAMAGE; DNA METHYLATION; DRUG SENSITIVITY; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC REGULATION; HUMAN; LAPAROTOMY; LIGAND BINDING; ONCOGENE H RAS; OVARY CARCINOMA; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW; THERAPY RESISTANCE; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; RNA INTERFERENCE;

EID: 79953829678     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.11.1     Document Type: Review

References (83)

1. Cannistra SA. Cancer of the ovary. N. Engl. J. Med. 351, 2519-2529 (2004).
2. Lengyel E. Ovarian cancer development and metastasis. Am. J. Pathol. 177(3), 1053-1064 (2010). Important overview concerning the biological behavior of ovarian cancer, from the site of origin to the peculiar mechanism of metastasization.
3. Kurman RJ, Shih I. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 34, 433-443 (2010).
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
5. Na YJ, Farley J, Zeh A et al. Ovarian cancer: markers of response. Int. J. Gynecol. Cancer 19(Suppl. 2), S21-S29 (2009).
6. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatinum and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34-43 (2006).
7. Ozols RF, Bookman MA, Connolly DC et al. Focus on epithelial ovarian cancer. Cancer Cell 5, 19-24 (2004).
8. Berkenblit A, Cannistra SA. Advances in the management of epithelial ovarian cancer. J. Reprod. Med. 50, 426-438 (2005).
9. Despierre E, Lambrechts D, Neven P et al. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol. Oncol. 117, 358-365 (2010).
10. Agarwal R, Kaye SB. Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann. Oncol. 16, 4-6 (2005).
11. Jin Z, el Deiry WS. Overview of cell death signaling pathways. Cancer Biol. Ther. 4, 139-163 (2005).
12. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25, 4798-4811 (2006).
13. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin. Cancer Res. 16, 1701-1708 (2010).
14. Villunger A, Michalak EM, Coultas L et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins PUMA and NOXA. Science 302, 1036-1038 (2003).
15. Jeffers JR, Parganas E, Lee Y et al. PUMA is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4, 321-328 (2003).
16. Tang D, Lotze MT, Kang R, Zeh HJ. Apoptosis promotes early tumorigenesis. Oncogene DOI:10.1038/onc.2010.573 (2010) (Epub ahead of print).
17. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell Biol. 11, 621-632 (2010). Describes, in great detail, the role of molecules involved in apoptotic pathways.
18. Li P, Nijhawan D, Budihardjo I et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91, 479-489 (1997).
19. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev. 13, 239-252 (1999).
20. Scaffidi C, Fulda S, Srinivasan A et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17, 1675-1687 (1998).
21. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94, 481-490 (1998).
22. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501 (1998).
23. Bagnoli M, Balladore E, Luison E et al. Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatinum pretreatment. Mol. Cancer Ther. 6, 762-772 (2007).
24. Algeciras-Schimnich A, Pietras EM, Barnhart BC et al. Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc. Natl Acad. Sci. USA 100, 11445-11450 (2003). Describes the different sensitivity of type I and type II tumor cell lines to structurally different chemotherapeutic drugs.
25. Bagnoli M, Canevari S, Mezzanzanica D. Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptormediated apoptosis in physiologic context and in cancer. Int. J. Biochem. Cell Biol. 42, 210-213 (2010). Comprehensive view of the cellular FLICE-inhibitory protein signaling pathway.
26. Safa AR, Day TW, Wu CH. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr. Cancer Drug Targets 8, 37-46 (2008).
27. Horak P, Pils D, Kaider A et al. Perturbation of the tumor necrosis factor-related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin. Cancer Res. 11, 8585-8591 (2005).
28. Mezzanzanica D, Balladore E, Turatti F et al. CD95-mediated apoptosis is impaired at receptor level by cellular FLICEinhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin. Cancer Res. 10, 5202-5214 (2004).
29. Abedini MR, Qiu Q, Yan X, Tsang BK. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 23, 6997-7004 (2004).
30. Abedini MR, Muller EJ, Brun J et al. Cisplatinum induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res. 68, 4511-4517 (2008).
31. Bagnoli M, Ambrogi F, Pilotti S et al. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome. Endocr. Relat. Cancer 16, 443-453 (2009).
32. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 23, 2950-2966 (2004).
33. Chen L, Park SM, Tumanov AV et al. CD95 promotes tumour growth. Nature 465, 492-496 (2010).
34. Sato T, Irie S, Kitada S, Reed JC. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 268, 411-415 (1995).
35. Schickel R, Park SM, Murmann AE, Peter ME. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol. Cell 38, 908-915 (2010).
36. Fiory F, Formisano P, Perruolo G, Beguinot F. Frontiers: PED/PEA-15, a multifunctional protein controlling cell survival and glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 297, E592-E601 (2009).
37. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 408, 307-310 (2000).
38. Canevari S, Gariboldi M, Reid JF, Bongarzone I, Pierotti MA. Molecular predictors of response and outcome in ovarian cancer. Crit. Rev. Oncol. Hematol. 60, 19-37 (2006).
39. Bernardini MQ, Baba T, Lee PS et al. Expression signatures of TP53 mutations in serous ovarian cancers. BMC Cancer 10, 237 (2010).
40. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159 (2008).
41. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854 (1993).
42. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004). Essential paper to understand miRNA processing, and their function as gene-expression regulators.
43. Sethupathy P, Megraw M, Hatzigeorgiou AG. A guide through present computational approaches for the identification of mammalian microRNA targets. Nat. Methods 3, 881-886 (2006).
44. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu. Rev. Med. 60, 167-179 (2009).
45. Mirnezami AH, Pickard K, Zhang L, Primrose JN, Packham G. MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur. J Surg. Oncol. 35, 339-347 (2009).
46. Wang Y, Lee CG. MicroRNA and cancer - focus on apoptosis. J. Cell. Mol. Med. 13, 12-23 (2009).
47. Vecchione A, Croce CM. Apoptomirs: small molecules have gained the license to kill. Endocr. Relat. Cancer 17, F37-F50 (2010). Summarizes the most recent findings on miRNA involvement in apoptotic processes.
48. Garofalo M, Condorelli GL, Croce CM, Condorelli G. MicroRNAs as regulators of death receptors signaling. Cell Death Differ. 17, 200-208 (2010).
49. Park SM, Peter ME. microRNAs and death receptors. Cytokine Growth Factor Rev. 19, 303-311 (2008).
50. Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res. 68, 8164-8172 (2008).
51. Ovcharenko D, Kelnar K, Johnson C, Leng N, Brown D. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res. 67, 10782-10788 (2007).
52. Tili E, Michaille JJ, Cimino A et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 179, 5082-5089 (2007).
53. Curtale G, Citarella F, Carissimi C et al. An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. Blood 115, 265-273 (2010).
54. Kurokawa M, Kornbluth S. Caspases and kinases in a death grip. Cell 138, 838-854 (2009).
55. Shell S, Park SM, Radjabi AR et al. Let-7 expression defines two differentiation stages of cancer. Proc. Natl Acad. Sci. USA 104, 11400-11405 (2007).
56. Tsang WP, Kwok TT. Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 13, 1215-1222 (2008).
57. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2, 647-656 (2002).
58. Cimmino A, Calin GA, Fabbri M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102, 13944-13949 (2005).
59. Calin GA, Ferracin M, Cimmino A et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353, 1793-1801 (2005). Demonstrates for the first time a unique miRNA signature associated with disease progression and patient prognosis.
60. Mott JL, Kobayashi S, Bronk SF, Gores GJ. miR-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26, 6133-6140 (2007).
61. Incoronato M, Garofalo M, Urso L et al. miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res. 70, 3638-3646 (2010).
62. Chen F, Zhu HH, Zhou LF et al. Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells. Oncol. Rep. 23, 1457-1462 (2010).
63. He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network - another piece in the tumour-suppression puzzle. Nat. Rev. Cancer 7, 819-822 (2007). Places miRNAs in a central role in a well-known tumor-suppressor network controlled by p53.
64. Georges SA, Biery MC, Kim SY et al. Coordinated regulation of cell cycle transcripts by p53-inducible microRNAs, miR-192 and miR-215. Cancer Res. 68, 10105-10112 (2008).
65. Braun CJ, Zhang X, Savelyeva I et al. p53-responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 68, 10094-10104 (2008).
66. Suzuki HI, Yamagata K, Sugimoto K et al. Modulation of microRNA processing by p53. Nature 460, 529-533 (2009).
67. Corney DC, Nikitin AY. microRNA and ovarian cancer. Histol. Histopathol. 23, 1161-1169 (2008).
68. Dahiya N, Morin PJ. microRNAs in ovarian carcinomas. Endocr. Relat. Cancer 17, F77-F89 (2010).
69. Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int. J. Biochem. Cell Biol. 42, 1262-1272 (2010). Gives an overview on all the miRNAs differentially expressed between ovarian cancer and normal counterpart and ovarian cancers with different sensitivity to therapies.
70. van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resistance. Int. J. Biochem. Cell Biol. 42, 1282-1290 (2010).
71. Yang N, Kaur S, Volinia S et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 68, 10307-10314 (2008).
72. Peter ME. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 8, 843-852 (2009).
73. Corney DC, Hwang CI, Matoso A et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin. Cancer Res. 16, 1119-1128 (2010).
74. Creighton CJ, Fountain MD, Yu Z et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res. 70, 1906-1915 (2010).
75. Valastyan S, Reinhardt F, Benaich N et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137, 1032-1046 (2009).
76. Yang H, Kong W, He L et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatinum resistance by targeting PTEN. Cancer Res. 68, 425-433 (2008).
77. Guan Y, Yao H, Zheng Z, Qiu G, Sun K. miR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int. J. Cancer DOI: 10.1002/ijc.25575 (2010) (Epub ahead of print).
78. Bhattacharya R, Nicoloso M, Arvizo R et al. miR-15a and miR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 69, 9090-9095 (2009).
79. Chen R, Alvero AB, Silasi DA et al. Regulation of IKKβ by miR-199a affects NF-κB activity in ovarian cancer cells. Oncogene 27, 4712-4723 (2008).
80. Bushati N, Cohen SM. microRNA functions. Annu. Rev. Cell Dev. Biol. 23, 175-205 (2007).
81. Bartel DP. microRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
82. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9, 102-114 (2008).
83. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840 (2010).